Uptravi Side Effects
Generic Name: selexipag
Note: This page contains side effects data for the generic drug selexipag. It is possible that some of the dosage forms included below may not apply to the brand name Uptravi.
Common side effects of Uptravi include: diarrhea, headache, jaw pain, limb pain, myalgia, nausea, vomiting, and flushing. Other side effects include: anemia, and decreased appetite. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to selexipag: oral tablet
As well as its needed effects, selexipag (the active ingredient contained in Uptravi) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking selexipag, check with your doctor immediately:Incidence not known:
- Blue lips and fingernails
- chest pain
- coughing that sometimes produces a pink frothy sputum
- difficult, fast, noisy breathing, sometimes with wheezing
- increased sweating
- pale skin
- swelling in the legs and ankles
Minor Side Effects
Some selexipag side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common:
- Decreased appetite
- feeling of warmth
- joint pain
- muscle aching or cramping
- muscle pains or stiffness
- pain in the jaw, arms, or legs
- redness of the face, neck, arms, and occasionally, upper chest
- swollen joints
For Healthcare Professionals
Applies to selexipag: oral tablet
The most frequently reported side effects included headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.[Ref]
Very common (10% or more): Headache (65%)[Ref]
Very common (10% or more): Diarrhea (42%), nausea (33%), vomiting (18%)[Ref]
Very common (10% or more): Jaw pain (26%), pain in extremity (17%), myalgia (16%), arthralgia (11%)[Ref]
Very common (10% or more): Flushing (12%)[Ref]
Very common (10% or more): Rash (11%)[Ref]
Frequency not reported: Pulmonary veno-occlusive disease[Ref]
Common (1% to 10%): Hyperthyroidism
Frequency not reported: Thyroid stimulating hormone decreased[Ref]
Common (1% to 10%): Anemia, hemoglobin decreased[Ref]
Common (1% to 10%): Appetite decreased[Ref]
1. "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.
It is possible that some side effects of Uptravi may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
More about Uptravi (selexipag)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.